Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19 - Seite 2

"We believe that this innovative device, which is designed to be affordable and easy to use, could represent an additional near-term protective option that could be particularly helpful in high-risk environments such as public transportation, shops, schools and other crowded, closed spaces", says Paolo Galfetti, CEO of APR.  "The initiation of this controlled, randomized clinical trial gets us closer to the objective of making this product available before year end specifically for use against COVID-19."

About APR Applied Pharma Research s.a. ("APR")

APR is an independent pharma company headquartered in Switzerland with subsidiaries in Italy and Germany focused, since more than 25 years, in the development and commercialization of products intended to improve the quality of life of patients and families dealing with serious diseases of high medical need. APR's portfolio includes products for the treatment of rare or niche diseases which are commercialized in about 50 countries worldwide either directly or through licensing and distribution agreements with selected partners. The pipeline includes products at different stage of development concentrated in 3 selected therapeutic areas: inherited metabolic recessive diseases, cancer supportive care and skin rare diseases. For more information, please visit: https://www.apr.ch/

About APR-AOS2020

APR-AOS2020 is an acid-oxidizing solution (AOS) containing hypochlorous acid at 0,005% certified and authorized in Europe on March 5^th 2021 as Class III Medical Device (Certificate Nr. EPT 0477.MDD.21/4200.1 having provisional name Sentinox). The device is intended for irrigation, cleansing and moistening of the nasal cavities and is indicated for (i) reducing the risk of infections caused by bacteria and viruses, including SARS-CoV-2, by lowering the nasal microbial load, (ii) symptomatic nasal care and (iii) nasal care in case of minor lesions/alterations of the nasal mucosa.

Logo - https://mma.prnewswire.com/media/1194581/APR_Applied_Pharma_Research_Logo.jpg

Contacts:

APR Applied Pharma Research s.a.
Paolo Galfetti, CEO
[e-mail]
[phone]

[1] https://link.springer.com/article/10.1007/s00405-021-06644-5